Overview

Adjuvant Avelumab in Merkel Cell Cancer

Status:
Recruiting
Trial end date:
2025-02-25
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Phase:
Phase 3
Details
Lead Sponsor:
University of Washington
Collaborators:
EMD Serono
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal
Avelumab